Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...agnosi...
...actors for Multidrug-Resistant PathogensHavi...
...robiologic Method...
...d IDSA suggest noninvasive sampling with semiqua...
...ve sampling with semiquantitative cultur...
...ggest that patients with suspected HAP (non-VAP)...
...iomarker...
...with suspected HAP/VAP, ATS and IDSA recommend...
...with suspected HAP/VAP, ATS and IDSA recommend u...
...nts with suspected HAP/VAP, ATS and IDSA re...
...with suspected HAP/VAP, ATS and IDSA suggest usi...
Treatment
...eatment
...itial...
...patients with ventilator-associated tracheob...
...ommend that all hospitals regularly generate...
...TS and IDSA recommend that empiric tr...
...h suspected VAP, ATS and IDSA recomm...
ATS and IDSA suggest including an agent a...
...gest including an agent active against methi...
...piric coverage for MRSA is indicated, ATS an...
...piric treatment that includes coverage f...
...uggest prescribing two antipseudomonal antibioti...
...nd IDSA suggest prescribing one antibiot...
...th suspected VAP, ATS and IDSA suggest avoiding a...
...with suspected VAP, ATS and IDSA suggest...
...TS and IDSA recommend that empiric anti...
...SA recommend that all hospitals regularly...
...tients being treated empirically for HAP,...
...atients with HAP who are being treated empir...
...atients with HAP who require empiric cov...
...h HAP who are being treated empirically and...
...th HAP who are being treated empirically,...
...nts with HAP who are being treated empiri...
...with HAP who are being treated empir...
...timizatio...
...th HAP/VAP, ATS and IDSA suggest that antibiot...
...led Antibiotic...
...or patients with VAP due to Gram-negat...
...thogen-Specific Therapy...
...DSA recommend that MRSAHAP/VAP be treated wi...
...patients with HAP/VAP due to P. aeruginosa, ATS...
...nts with HAP/VAP due to P. aerugin...
...ith HAP/VAP due to P. aeruginosa who are not...
...ents with HAP/VAP due to P. aeruginosa w...
...or patients with HAP/VAP due to P. aerugi...
...atients with HAP/VAP due to extend...
...th HAP/VAP caused by Acinetobacter spec...
...ts with HAP/VAP caused by Acinetobact...
...and IDSA suggest adjunctive inhaled...
...patients with HAP/VAP caused by Acinetobac...
In patients with HAP/VAP caused by Acinetobac...
...ents with HAP/VAP caused by a carbapenem-...
...ATS and IDSA suggest adjunctive inhaled c...
...ients with VAP, ATS and IDSA recommend a 7-...
...patients with HAP, ATS and IDSA recommend a 7-day...
...with HAP/VAP, ATS and IDSA suggest that a...
...nts with HAP/VAP, ATS and IDSA suggest using...
For patients with suspected HAP/VAP, ATS and...
...ble 2. Recommended Initial Empiric Antibiotic Ther...
.... Empiric Treatment Options for Suspected MRSA/P...